Several brokerages have updated their recommendations and price targets on shares of Regeneron Pharmaceuticals (NASDAQ: REGN) in the last few weeks:

  • 10/16/2017 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They wrote, “Cara announced this morning that the company has completed an End of Phase 2 mtg with FDA around CR845 in Pruritus associated with Chronic Kidney Disease. We spoke w/ mgmt for an update. Cara plans to initiate one Phase 3 trial of IV CR845 in the U.S. in 4Q17, followed by a second Phase 3 trial in Europe in early 2018. Details on size and design are expected during 3Q17 conference call in a few wks. Although mgmt not providing guidance on timing to top-line results, we believe NDA submission YE19 and launch YE20 still appears feasible.””
  • 10/16/2017 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 10/10/2017 – Regeneron Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “With Eylea accounting for the majority of revenues at Regeneron, Regeneron relies heavily on the drug for growth. In the U.S., the company is witnessing increased competitor discounts and rebates. Sub-par performance of the product will hurt the stock as Eylea is Regeneron’s key growth driver. Prospects of PCSK9 inhibitors, a new class of cholesterol-lowering treatments with blockbuster potential, gained instant popularity even before hitting the market. However, sales of Praluent have failed to impress as the drug is facing significant payer utilization management restrictions in the U.S. and limited market access in Europe, which is resulting in a low volume of prescriptions being dispensed. Nevertheless, the approval of new drugs like Kevzara and Dupixent provide a significant boost to the top-line. Shares have outperformed the industry so far in 2017.”
  • 10/6/2017 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $500.00 price target on the stock, up previously from $471.00.
  • 10/6/2017 – Regeneron Pharmaceuticals had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $490.00 price target on the stock, up previously from $450.00.
  • 10/4/2017 – Regeneron Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “Regeneron’s key growth driver, Eylea, continues to drive revenues on market share gains and the company is expanding the drug's label for additional indications. The FDA’s approval of Dupixent for atopic dermatitis was a major boost to the company’s portfolio and the company is working to expand its label. The drug was recently approved in Europe and we expect sales to get  a boost from geographic expansion. Further, the approval of Kevzara (sarilumab) for the treatment of moderately-to-severely active rheumatoid arthritis both in the United States and Europe has boosted the company’s portfolio. Shares have outperformed the industry so far in 2017. We expect the new drug approvals and label expansion of Eylea will continue to boost Regeneron’s performance. However, sales of Praluent have failed to impress.”
  • 10/2/2017 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $435.00 price target on the stock.
  • 9/29/2017 – Regeneron Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $540.00 price target on the stock.
  • 9/27/2017 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 9/21/2017 – Regeneron Pharmaceuticals had its price target lowered by analysts at UBS AG from $535.00 to $500.00. They now have a “buy” rating on the stock.
  • 9/14/2017 – Regeneron Pharmaceuticals is now covered by analysts at Royal Bank Of Canada. They set a “sector perform” rating and a $475.00 price target on the stock.
  • 9/11/2017 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Credit Suisse Group. They now have a $485.00 price target on the stock.
  • 9/11/2017 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $522.00 price target on the stock.
  • 9/8/2017 – Regeneron Pharmaceuticals had its “sell” rating reaffirmed by analysts at Robert W. Baird. They now have a $408.00 price target on the stock.
  • 9/7/2017 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $575.00 price target on the stock.
  • 9/6/2017 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $566.00 price target on the stock.
  • 8/24/2017 – Regeneron Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 8/23/2017 – Regeneron Pharmaceuticals had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $450.00 price target on the stock.

Shares of Regeneron Pharmaceuticals, Inc. (REGN) traded down 0.70% during midday trading on Tuesday, reaching $442.56. The company’s stock had a trading volume of 644,310 shares. The company has a 50 day moving average price of $456.72 and a 200-day moving average price of $455.81. The stock has a market capitalization of $46.93 billion, a PE ratio of 44.40 and a beta of 1.63. Regeneron Pharmaceuticals, Inc. has a 52 week low of $325.35 and a 52 week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.82 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.94 EPS for the current year.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi acquired 166,415 shares of the business’s stock in a transaction on Thursday, August 24th. The stock was bought at an average price of $480.93 per share, for a total transaction of $80,033,965.95. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Robert E. Landry sold 189 shares of the stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the sale, the chief financial officer now owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. In the last quarter, insiders sold 89,468 shares of company stock valued at $42,312,448. 10.80% of the stock is owned by insiders.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.